Brazil Antibody Drug Conjugates Contract Manufacturing Market Size & Outlook
Related Markets
Brazil antibody drug conjugates contract manufacturing market highlights
- The Brazil antibody drug conjugates contract manufacturing market generated a revenue of USD 266.6 million in 2024 and is expected to reach USD 487.7 million by 2030.
- The Brazil market is expected to grow at a CAGR of 10.5% from 2025 to 2030.
- In terms of segment, myeloma was the largest revenue generating condition in 2024.
- Lymphoma is the most lucrative condition segment registering the fastest growth during the forecast period.
Antibody drug conjugates contract manufacturing market data book summary
| Market revenue in 2024 | USD 266.6 million |
| Market revenue in 2030 | USD 487.7 million |
| Growth rate | 10.5% (CAGR from 2025 to 2030) |
| Largest segment | Myeloma |
| Fastest growing segment | Lymphoma |
| Historical data | 2018 - 2023 |
| Base year | 2024 |
| Forecast period | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Myeloma, Lymphoma, Breast Cancer |
| Key market players worldwide | Sterling Check Corp, Recipharm, Lonza Group Ltd, Catalent Inc, Sartorius AG, WuXi Biologics (Cayman) Inc, Samsung BioLogics, Piramal Healthcare, AbbVie Inc, Merck KGaA |
Other key industry trends
- In terms of revenue, Brazil accounted for 3.0% of the global antibody drug conjugates contract manufacturing market in 2024.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Latin America, Brazil antibody drug conjugates contract manufacturing market is projected to lead the regional market in terms of revenue in 2030.
- Brazil is the fastest growing regional market in Latin America and is projected to reach USD 487.7 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Antibody Drug Conjugates Contract Manufacturing Market Scope
Antibody Drug Conjugates Contract Manufacturing Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Piramal Healthcare | View profile | 5001-10000 | Mumbai, Maharashtra, India, Asia | http://www.piramalpharmasolutions.com |
| Sterling Check Corp | View profile | 5700 | 6150 Oak Tree Boulevard, Suite 490, Independence, OH, United States, 44131 | https://www.sterlingcheck.com |
| Samsung BioLogics | View profile | 1001-5000 | Incheon, Inch'on-jikhalsi, South Korea, Asia | https://www.samsungbiologics.com/ |
| Recipharm | View profile | 1001-5000 | Jordbro, Stockholms Lan, Sweden, Europe | http://www.recipharm.com |
| Catalent Inc | View profile | 17219 | 14 Schoolhouse Road, Somerset, NJ, United States, 08873 | https://www.catalent.com |
| WuXi Biologics (Cayman) Inc | View profile | 12740 | No. 108, Meiliang Road, Mashan Binhu District, Wuxi, China, People's Republic of, 214092 | https://www.wuxibiologics.com |
| Sartorius AG | View profile | 14338 | Otto-Brenner-Strasse 20, Gottingen, NI, Germany, 37079 | https://www.sartorius.com |
| Lonza Group Ltd | View profile | 18000 | Muenchensteinerstrasse 38, Basel, Switzerland, CH-4002 | https://www.lonza.com |
| AbbVie Inc | View profile | 50000 | 1 North Waukegan Road, North Chicago, IL, United States, 60064-6400 | http://www.abbvieinvestor.com |
| Merck KGaA | View profile | 62345 | Frankfurter Strasse 250, Darmstadt, HE, Germany, 64293 | https://www.emdgroup.com |
Brazil antibody drug conjugates contract manufacturing market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to antibody drug conjugates contract manufacturing market will help companies and investors design strategic landscapes.
Myeloma was the largest segment with a revenue share of 55.1% in 2024. Horizon Databook has segmented the Brazil antibody drug conjugates contract manufacturing market based on myeloma, lymphoma, breast cancer covering the revenue growth of each sub-segment from 2018 to 2030.
The presence of a significant number of drug contract manufacturing facilities and FDA- and EMA-approved sites in Brazil is contributing to the local demand for contract manufacturing. This is expected to have a positive impact on the market.
According to the International Agency for Research on Cancer, cancer incidence in Brazil in 2020 was nearly 214 cases per 100,000 individuals. Among the leading forms of cancer, the most prevalent were prostrate and breast cancers.
There is expected to be a 50% growth in cancer prevalence by 2025, owing primarily to a rapidly aging population. The high cancer burden is expected to improve the adoption of ADCs in the country and drive the market.
Reasons to subscribe to Brazil antibody drug conjugates contract manufacturing market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Brazil antibody drug conjugates contract manufacturing market databook
-
Our clientele includes a mix of antibody drug conjugates contract manufacturing market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Brazil antibody drug conjugates contract manufacturing market , including forecasts for subscribers. This country databook contains high-level insights into Brazil antibody drug conjugates contract manufacturing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Brazil antibody drug conjugates contract manufacturing market size, by condition, 2018-2030 (US$M)
Brazil Antibody Drug Conjugates Contract Manufacturing Market Outlook Share, 2024 & 2030 (US$M)
Related industry reports
Related statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
